home / stock / lpcn / lpcn short
Short Information | Lipocine Inc. (NASDAQ:LPCN)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 231,304 |
Total Actual Volume | 3,098,746 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 11,565 |
Average Short Percentage | 10.86% |
Is there a LPCN Short Squeeze or Breakout about to happen?
See the LPCN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-24-2024 | $4.79 | $4.44 | $5.02 | $4.4 | 66,372 | 7,119 | 10.73% |
04-23-2024 | $5.06 | $4.8 | $5.13 | $4.7001 | 75,392 | 5,389 | 7.15% |
04-22-2024 | $5.19 | $5.07 | $5.4 | $5.0301 | 21,546 | 3,628 | 16.84% |
04-19-2024 | $5.41 | $5.27 | $5.5299 | $5.26 | 11,286 | 1,721 | 15.25% |
04-18-2024 | $5.24 | $5.44 | $5.53 | $5.22 | 21,350 | 2,446 | 11.46% |
04-17-2024 | $4.74 | $5.32 | $5.435 | $4.6998 | 34,899 | 2,413 | 6.91% |
04-16-2024 | $5.3 | $4.76 | $5.3 | $4.68 | 37,039 | 4,264 | 11.51% |
04-15-2024 | $5.67 | $5.355 | $5.67 | $5.1177 | 95,973 | 5,315 | 5.54% |
04-12-2024 | $6.11 | $5.81 | $6.25 | $5.52 | 214,524 | 50,613 | 23.59% |
04-11-2024 | $6.3 | $6.41 | $7.15 | $5.63 | 2,204,801 | 116,273 | 5.27% |
04-10-2024 | $5.8 | $6.51 | $6.7 | $5.6 | 51,900 | 2,519 | 4.85% |
04-09-2024 | $5.335 | $5.77 | $5.88 | $5.335 | 96,272 | 13,982 | 14.52% |
04-08-2024 | $4.9 | $5.26 | $5.38 | $4.9 | 19,761 | 1,713 | 8.67% |
04-05-2024 | $4.58 | $4.8 | $4.8222 | $4.53 | 23,616 | 1,900 | 8.05% |
04-04-2024 | $4.87 | $4.61 | $4.97 | $4.54 | 25,305 | 2,243 | 8.86% |
04-03-2024 | $5.02 | $4.93 | $5.075 | $4.93 | 4,720 | 627 | 13.28% |
04-02-2024 | $5.21 | $4.97 | $5.225 | $4.77 | 10,661 | 792 | 7.43% |
04-01-2024 | $5.11 | $5.3 | $5.3 | $5.02 | 13,412 | 1,149 | 8.57% |
03-28-2024 | $5.03 | $5.2 | $5.3021 | $4.85 | 49,035 | 2,098 | 4.28% |
03-27-2024 | $4.95 | $5.1288 | $5.3 | $4.95 | 20,882 | 5,100 | 24.42% |
News, Short Squeeze, Breakout and More Instantly...
2024-04-11 09:01:37 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Lipocine Inc. (NASDAQ: LPCN ) results from a Phase 2 clinical trial including LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, which sho...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fa...
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52...